v3.25.4
Segment, Geographic and Other Revenue Information - Schedule of Significant Biopharma Segment Expenses (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Total revenues [1] $ 62,579 $ 63,627 $ 59,553
Cost of sales [2],[3] 16,067 17,851 24,954
Selling, informational and administrative expenses [2] 13,794 14,730 14,771
Research and development expenses [2] 10,437 10,822 10,679
Acquired in-process research and development expenses 1,613 108 194
Other (income)/deductions––net 6,724 4,388 222
Income from continuing operations before provision/(benefit) for taxes on income [4],[5],[6] 7,520 8,023 1,058
Biopharma [Member]      
Segment Reporting Information [Line Items]      
Total revenues 61,199 62,400 58,237
Cost of sales 13,505 14,997 22,666
Selling, informational and administrative expenses [7] 9,637 10,210 10,391
Research and development expenses 9,183 9,532 9,763
Acquired in-process research and development expenses 113 108 194
Other (income)/deductions––net (581) (416) (543)
Income from continuing operations before provision/(benefit) for taxes on income [7] 29,342 27,969 15,767
Biopharma [Member] | Primary Care [Member]      
Segment Reporting Information [Line Items]      
Total revenues 26,820 30,135 30,799
Biopharma [Member] | Comirnaty [Member] | Primary Care [Member]      
Segment Reporting Information [Line Items]      
Total revenues 4,367 5,353 11,220
Biopharma [Member] | Paxlovid [Member] | Primary Care [Member]      
Segment Reporting Information [Line Items]      
Total revenues [8] 2,362 5,716 1,279
Biopharma [Member] | Excluding Comirnaty and Paxlovid [Member] | Primary Care [Member]      
Segment Reporting Information [Line Items]      
Total revenues $ 54,470 $ 51,331 $ 45,738
[1] Revenues are primarily attributed to countries based on the location of the customer.
[2] Exclusive of amortization of intangible assets.
[3] See Note 17A.
[4] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include costs related to manufacturing and supply, sales and marketing activities, R&D, and medical and safety activities that are associated with products in our Biopharma segment. Effective in the third quarter of 2025, certain expenses for corporate affairs, such as for U.S. policy and government relations, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $170 million and $156 million in 2024 and 2023, respectively, from Other business activities to Biopharma to conform to the current period presentation.
[5] 2024 v. 2023––The reduction in the domestic loss in 2024 versus the domestic loss in 2023 is primarily attributable to increased revenues offset by higher restructuring charges and asset impairment charges. The increase in the international income is primarily attributable to lower: Cost of Sales, Restructuring charges and certain acquisition-related costs and asset impairment charges.
[6] 2025 v. 2024––The domestic income in 2025 versus the domestic loss in 2024 is primarily attributable to a reduction in operating expenses and restructuring charges, partially offset by higher asset impairment and legal charges. The decrease in the international income in 2025 versus international income in 2024 is primarily attributable to higher asset impairment charges. For 2025, the data in this table conforms to the updated income tax disclosure guidance in accordance with ASU 2023-09.
[7] As described above, certain Selling, informational and administrative expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. Prior year amounts have been recast to conform to the current period presentation.
[8] 2024 included (i) a $771 million favorable final adjustment recorded in the first quarter to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023, and (ii) $442 million of revenue recorded in the third quarter in connection with the creation of the U.S. SNS. 2023 included a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.